[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

SE393381B - Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat - Google Patents

Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat

Info

Publication number
SE393381B
SE393381B SE7116090A SE1609071A SE393381B SE 393381 B SE393381 B SE 393381B SE 7116090 A SE7116090 A SE 7116090A SE 1609071 A SE1609071 A SE 1609071A SE 393381 B SE393381 B SE 393381B
Authority
SE
Sweden
Prior art keywords
underivatives
azapurin
preparation
analogical procedure
analogical
Prior art date
Application number
SE7116090A
Other languages
English (en)
Inventor
B J Broughton
B J Large
S M Marshall
D L Pain
K R H Wooldridge
Original Assignee
May & Baker Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by May & Baker Ltd filed Critical May & Baker Ltd
Publication of SE393381B publication Critical patent/SE393381B/sv

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/47—One nitrogen atom and one oxygen or sulfur atom, e.g. cytosine
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D317/00—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D317/08—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3
    • C07D317/44—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D317/46—Heterocyclic compounds containing five-membered rings having two oxygen atoms as the only ring hetero atoms having the hetero atoms in positions 1 and 3 ortho- or peri-condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • C07D317/48—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring
    • C07D317/62—Methylenedioxybenzenes or hydrogenated methylenedioxybenzenes, unsubstituted on the hetero ring with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to atoms of the carbocyclic ring
    • C07D317/68—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
SE7116090A 1970-12-15 1971-12-14 Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat SE393381B (sv)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GB5955270 1970-12-15
GB5955670 1970-12-15
GB4975671A GB1338235A (en) 1970-12-15 1971-10-26 Azapurinones
GB5345771 1971-11-17

Publications (1)

Publication Number Publication Date
SE393381B true SE393381B (sv) 1977-05-09

Family

ID=27449009

Family Applications (1)

Application Number Title Priority Date Filing Date
SE7116090A SE393381B (sv) 1970-12-15 1971-12-14 Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat

Country Status (25)

Country Link
US (1) US3987160A (sv)
JP (1) JPS5310599B1 (sv)
AR (4) AR192602A1 (sv)
AT (4) AT315839B (sv)
AU (1) AU458277B2 (sv)
BE (1) BE776683A (sv)
BG (3) BG20807A3 (sv)
CH (5) CH552610A (sv)
DD (1) DD95007A5 (sv)
DE (1) DE2162096A1 (sv)
DK (1) DK141249B (sv)
FI (1) FI53457C (sv)
FR (1) FR2118078B1 (sv)
GB (1) GB1338235A (sv)
HK (1) HK42177A (sv)
HU (1) HU165079B (sv)
IE (1) IE35897B1 (sv)
IL (1) IL38364A (sv)
IS (1) IS1099B6 (sv)
LU (1) LU64457A1 (sv)
NL (1) NL174943C (sv)
NO (1) NO134257C (sv)
OA (1) OA03930A (sv)
SE (1) SE393381B (sv)
ZM (1) ZM18971A1 (sv)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1493685A (en) * 1970-12-15 1977-11-30 May & Baker Ltd 8-azapurinones
BE792648A (fr) * 1971-12-13 1973-06-12 May & Baker Ltd Derives de l'isoquinoleine
FR2406638A1 (fr) * 1977-10-21 1979-05-18 May & Baker Ltd Nouvelles aza-8 purinones-6, leur preparation et les compositions pharmaceutiques les contenant
EP0007727B1 (en) * 1978-07-24 1983-11-30 Beecham Group Plc Benzopyranotriazoles, preparation of these compounds and pharmaceutical composition containing them
JPS60226887A (ja) * 1984-04-25 1985-11-12 Dai Ichi Seiyaku Co Ltd トリアゾロピリミジン誘導体
CA1303037C (en) * 1987-02-02 1992-06-09 Smith Kline & French Laboratories Limited Purinone derivatives as bronchodilators vasodilators and anti-allergic agents
US5204353A (en) * 1987-04-07 1993-04-20 Ciba-Geigy Corporation 3-benzyl-3H-1,2,3-triazolo[4,5-d]pyrimidines, compositions thereof, and method of treating epilepsy therewith
DE3873812D1 (de) * 1987-04-07 1992-09-24 Ciba Geigy Ag 3h-1,2,3-triazolo(4,5-d)pyrimidine.
FR2618073B1 (fr) * 1987-07-16 1990-09-07 Pf Medicament Comprimes de type a matrice hydrophile a base de salbutamol et leur procede de preparation
GB8817651D0 (en) * 1988-07-25 1988-09-01 Smith Kline French Lab Chemical compounds
DE4211239C2 (de) * 1992-04-03 1995-11-16 Max Planck Gesellschaft Arzneimittel gegen Herz-Kreislauf-Erkrankungen
US5734053A (en) * 1992-06-26 1998-03-31 Pfizer Inc Purinone antianginal agents
GB9213623D0 (en) * 1992-06-26 1992-08-12 Pfizer Ltd Therapeutic agents
GB9311920D0 (en) 1993-06-09 1993-07-28 Pfizer Ltd Therapeutic agents
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6080428A (en) * 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6129930A (en) * 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US20080045573A1 (en) * 1993-09-20 2008-02-21 Bova David J Methods and Sustained Release Nicotinic Acid Compositions for Treating Hyperlipidemia
GB9404485D0 (en) * 1994-03-09 1994-04-20 Cancer Res Campaign Tech Benzamide analogues
CH693954A5 (de) 1997-11-12 2004-05-14 Bayer Ag 2-Phenyl-substituierte Imidazotriazinone als Phosphodiesterase Inhibitoren.
DE19838705A1 (de) * 1998-08-26 2000-03-02 Bayer Ag Neue Dihydro-(1,2,3)-triazolo-[4,5-d]pyrimidin-7-one
IT1318674B1 (it) * 2000-08-08 2003-08-27 Nicox Sa Faramaci per l'incontinenza.
DE10232113A1 (de) 2002-07-16 2004-01-29 Bayer Ag Vardenafil Hydrochlorid Trihydrat enthaltende Arzneimittel
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE102005009240A1 (de) 2005-03-01 2006-09-07 Bayer Healthcare Ag Arzneiformen mit verbesserten pharmakokinetischen Eigenschaften
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
JP5546451B2 (ja) 2007-06-04 2014-07-09 シナジー ファーマシューティカルズ インコーポレイテッド 胃腸の障害、炎症、癌および他の障害の処置に有用なグアニル酸シクラーゼのアゴニスト
EP2810951B1 (en) 2008-06-04 2017-03-15 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
EP3241839B1 (en) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
DK2681236T3 (en) 2011-03-01 2018-04-16 Synergy Pharmaceuticals Inc PROCEDURE FOR MANUFACTURING GUANYLATE CYCLASE-C-AGONISTS
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
JP2016514671A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド グアニル酸シクラーゼのアゴニストおよびその使用
EP2968439A2 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
EP4424697A2 (en) 2013-06-05 2024-09-04 Bausch Health Ireland Limited Ultra-pure agonists of guanylate cyclase c, method of making and using same
EP3884935B1 (en) 2013-08-09 2023-06-14 Ardelyx, Inc. Compounds and methods for inhibiting phosphate transport
BR112019012251A2 (pt) 2016-12-14 2019-11-05 Respira Therapeutics Inc métodos e composições para tratamento de hipertensão pulmonar e outros distúrbios pulmonares
TWI845600B (zh) 2019-01-24 2024-06-21 美商普羅米修斯生物科學股份有限公司 Gpr35調節劑
CN114340631A (zh) 2019-05-21 2022-04-12 阿德利克斯股份有限公司 用于降低患者的血清磷酸盐的组合
WO2022020617A1 (en) * 2020-07-23 2022-01-27 Prometheus Biosciences, Inc. Therapeutic agents targeting gpr35

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2407204A (en) * 1944-07-22 1946-09-03 American Cyanamid Co Triazolo (d) pyrimidines and methods of preparing the same
US2993039A (en) * 1959-11-06 1961-07-18 Upjohn Co Preparing nu-glycosides of aldose and ketose sugars

Also Published As

Publication number Publication date
IL38364A (en) 1975-08-31
NL174943C (nl) 1984-09-03
AT319235B (de) 1974-12-10
AT315838B (de) 1974-06-10
IE35897B1 (en) 1976-06-23
FR2118078A1 (sv) 1972-07-28
BE776683A (fr) 1972-06-14
AU3686771A (en) 1973-06-21
AR199467A1 (es) 1974-09-09
AR192602A1 (es) 1973-02-28
DK141249B (da) 1980-02-11
IL38364A0 (en) 1972-02-29
DK141249C (sv) 1980-08-04
CH550814A (fr) 1974-06-28
GB1338235A (en) 1973-11-21
IS2047A7 (is) 1972-06-16
HK42177A (en) 1977-08-19
FI53457B (sv) 1978-01-31
AR192689A1 (es) 1973-02-28
CH556860A (de) 1974-12-13
BG20807A3 (bg) 1975-12-20
LU64457A1 (sv) 1972-08-23
HU165079B (sv) 1974-06-28
IE35897L (en) 1972-06-15
US3987160A (en) 1976-10-19
DE2162096A1 (de) 1972-07-06
DE2162096C2 (sv) 1988-02-11
OA03930A (fr) 1975-08-14
AR199468A1 (es) 1974-09-09
FR2118078B1 (sv) 1975-08-01
NL174943B (nl) 1984-04-02
JPS5310599B1 (sv) 1978-04-14
CH552610A (fr) 1974-08-15
BG20805A3 (bg) 1975-12-20
NO134257C (sv) 1976-09-08
FI53457C (fi) 1978-05-10
AT317211B (de) 1974-08-26
DD95007A5 (sv) 1973-01-12
CH555351A (fr) 1974-10-31
ZM18971A1 (en) 1972-08-21
AU458277B2 (en) 1975-02-20
NL7117142A (sv) 1972-06-19
BG20806A3 (bg) 1975-12-20
NO134257B (sv) 1976-05-31
IS1099B6 (is) 1982-11-18
AT315839B (de) 1974-06-10
CH546779A (fr) 1974-03-15

Similar Documents

Publication Publication Date Title
SE393381B (sv) Analogiforfarande for framstellning av 8-azapurin - 6 - onderivat
SE383887B (sv) Analogiforfarande for framstellning av alfa-amino-cyklohexadienyl-alkylen-penicilliner
SE390304B (sv) Analogiforfarande for framstellning av 4-hydroxi-5-etyl-6-fonylpyrimidin
SE394678B (sv) Analogiforfarande for framstellning av pyridokinolinderivat
SE406197B (sv) Analogiforfarande for framstellning av 4-aminokinazolinderivat
NO138883C (no) Fremgangsmaate for fremstilling av oksiranforbindelser
SE400292B (sv) Forfarande for framstellning av benshydryl-3-karbamoyloximetyl-7-tienylacetamido-7-metoxidecefalosporanat
SE399701B (sv) Forfarande for framstellning av hydroxyalkyldiamin
SE394436B (sv) Forfarande for framstellning av 7-halogen-linkomyciner
SE380273B (sv) Forfarande for framstellning av tiopyrimidinderivat
SE385011B (sv) Forfarande for framstellning av alfa-linkosaminider
SE399069B (sv) Analogiforfarande for framstellning av triazolo-pyridino-isokinolin-derivat
SE395897B (sv) Forfarande for framstellning av 7beta-acylamido-3-metyl-cef-3-em-4-karbonsyror
SE397090B (sv) Forfarande for framstellning av hydroxipyrimidiner
SE405478B (sv) Forfarande for framstellning av alfa-sulfoacylcefalosporiner
SE408418B (sv) Forfarande for framstellning av 5-fluor-pyrimidiner
SE395699B (sv) Forfarande for framstellning av kinuklidin-kinolinderivat
SE388611B (sv) Analogiforfarande for framstellning av 1,4-bensodiazeponderivat
SE380795B (sv) Forfarande for framstellning av tiokarbamider
SE411759B (sv) Forfarande for framstellning av erytromycyliminforeningar
SE398114B (sv) Analogiforfarande for framstellning av aminoetrar
SE380520B (sv) Forfarande for framstellning av 1-cinnamylidenamino-3-bensylidenaminoguanidin
SE382046B (sv) Forfarande for framstellning av 1-aryloxi-2-propanol
SE404803B (sv) Analogiforfaranden for framstellning av pyrido-diazepiner
SE382051B (sv) Forfarande for framstellning av 3-sulfonamid-4-hydroxifenyl-2-piperidylkarbinoler